Business Services Industry
Zacks Bull and Bear of the Day Highlights: IBM Corporation, United Therapeutics, Greatbatch, Genuine Parts and School Specialty
Business Wire, August 27, 2008
CHICAGO -- Zacks Equity Research highlights IBM Corporation (NYSE: IBM) as the Bull of the Day and United Therapeutics (Nasdaq: UTHR) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Greatbatch, Inc. (NYSE: GB), Genuine Parts Co. (NYSE: GPC) and School Specialty (Nasdaq: SCHS).
Full analysis of all these stocks is available at http://at.zacks.com/?id=2676.
Here is a synopsis of all five stocks:
Bull of the Day: IBM Corporation (NYSE: IBM)
With over half of its revenue (58%) coming from outside the United States, IBM Corporation has been insulated from recent weakness in the U.S. economy than many of its peers. Although this trend may be ending as the U.S. economy picks up strength relative to Europe, IBM should continue to benefit from its focus on faster-growing markets through a series of acquisitions and divestiture of mature businesses.
Moreover, its position in emerging markets should continue to help drive growth. We maintain our Buy rating on IBM shares and a target price of $140.00.
Bear of the Day: United Therapeutics (Nasdaq: UTHR)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of therapeutic products for patients with chronic and life-threatening diseases. It offers products primarily in three therapeutic areas, including cardiovascular, cancer, and infectious diseases.
Although we believe current business fundamentals are solid, we are seeing several potential hiccups coming in the next year. And, with the stock up 65% over the past twelve months and currently trading at 50x our 2008 EPS estimate, we believe investors are pricing the stock for near flawless execution. Expectations are high, and any slip-up, even minor, may cause a sell-off in the shares. As a result, we are initiating with a Sell rating and an $82 price target.
Latest Posts on the Zacks Analyst Blog:
Greatbatch, Inc. (NYSE: GB)
Greatbatch is a leading producer and supplier of batteries, capacitors, and components used in implantable medical devices through its Implantable Medical Components (IMC) business.
The company reported second quarter top-line above expectations primarily due to acquisitions and strong end-market growth. However, EPS exceeded our expectations by a penny on lower R&D spending. The management provides adjusted 2008 EPS guidance of $1.20-$1.50. Our 2008 EPS estimates increase on positive news surrounding new products and promising innovations, and diversification beyond the CRM original equipment manufacturers, now less than 50% of Q208 sales.
Genuine Parts Co. (NYSE: GPC)
Genuine Parts has undertaken various initiatives such as product line expansion, penetration into new markets and acquisitions to boost sales and earnings. Genuine Parts has been diversifying its revenue base to reduce excessive dependence on the automotive replacement market.
The company's electronic and industrial parts businesses are showing impressive performance and it has a strong balance sheet. However, our optimism is dampened by the sluggish automotive and office products industries in the U.S. Considering these factors, we maintain our Hold recommendation with a target price of $43.
School Specialty (Nasdaq: SCHS)
In the first quarter, School Specialty, Inc.'s earnings per share were $0.16 below the consensus estimate and $0.15 below our estimate. In addition, the management updated its guidance for fiscal 2009. The company continues to expect revenue of $1.08-$1.11 billion, but it lowered its EPS guidance from $2.27-$2.43 to $2.23-$2.39 to account for a $0.04/share cost to closing a distribution center in the second quarter.
We are slightly reducing our 2009 EPS from $2.30 to $2.28 but leaving our fiscal 2010 EPS estimate at $2.45. School Specialty's industry-leading market position and cost-cutting efforts are offset by growing competitive pressures and limited organic growth prospects. We maintain our Hold rating on the stock.
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=2649.
About the Bull and Bear of the Day
Every day, the analysts at Zacks Equity Research select two stocks that are likely to outperform (Bull) or underperform (Bear) the markets over the next 3-6 months.
About the Analyst Blog
Updated throughout every trading day, the Analyst Blog provides analysis from Zacks Equity Research about the latest news and events impacting stocks and the financial markets.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=2677.
- 5 Rules for Immediate Annuities
- Death in the Family: 12 Things to Do Now
- Dumbest Things You Do With Your Money
- 6 Online Networking Mistakes to Avoid
- 401(k) Mistakes to Avoid
- 5 Economic Scenarios to Keep You Up at Night
- The Real ‘Best Places to Retire’
- Best Credit Cards for You
- 12 Tough Questions to Ask Your Parents
- The Real ‘Best Colleges’
- Home Buyer Tax Credit: How to Cash In
- Why You Shouldn't Bash Cash
- 8 Phony 'Bargains' and Better Alternatives
- Danger: 3 Debit Card Scams to Avoid
- 6 Myths About Gas Mileage
- 29 Fees We Hate Most
- Quick and Easy Ways to Boost Returns
- Best Stocks to Buy Now
- Lower Your Taxes: 10 Moves to Make Now
- New Jobs: 8 Lessons from Real-Life Career Switchers
- The New Job Market: Who Wins and Who Loses?
- Health Care Reform's Public Option: Everything You Need to Know
- Volunteer Work When Unemployed: Should You Work for Free?
- Whose Recovery Is This?
- Long-Term-Care Insurance: 4 Biggest Risks to Avoid
Most Recent Business Articles
- Psyadon Pharmaceuticals, Inc. Announces Regulatory Milestones and the Initiation of a Clinical Trial of Ecopipam in Lesch-Nyhan Disease
- Emergence of “Femtomedicine” - New Frontier of Biomed Sciences - Reported at First Global Congress on Nano Medicine
- Research and Markets: Ethiopia Power Market Outlook to 2020
- Research and Markets: Orphan Drugs in Asia-Pacific: from Designation to Pricing, Funding & Market Access
- Research and Markets: Now You See It - TV Program Sponsorship & Product Placement in China
Most Recent Business Publications
Most Popular Business Articles
- 7 tips for effective listening: productive listening does not occur naturally. It requires hard work and practice - Back To Basics - effective listening is a crucial skill for internal auditors
- FHM Features Anna Benson, Baseball's Hottest Wife
- Building a DNA database: the federal government has just enacted two bills related to DNA. The first would drive the collection of DNA from all infants. The second would attempt to prevent the DNA that is collected from being misused
- America's most wanted j-o-b-s - 10 hottest employment opportunities
- Developmental sequence in small groups


